https://ift.tt/pnED7n
(Reuters) - A U.S. judge has ruled that investors who claimed that Theranos Inc defrauded them into investing indirectly in the company by touting revolutionary blood-testing technology that never existed cannot pursue their claims as a class action.
Read more
0 comments:
Post a Comment